The key finding
A 2026 review in Nutrients highlights a critical gap in phenylketonuria (PKU) research: while middle childhood through early adulthood has been extensively studied for cognitive outcomes, researchers have paid far less attention to the cognitive functioning of very young children and older adults with PKU. This oversight matters because early brain development sets the foundation for lifelong cognitive abilities, and older adults with PKU may face unique risks for age-related cognitive decline that haven’t been properly investigated.
What the study looked like
This is a narrative review that examined the existing body of research on cognitive functioning in people with PKU across different life stages. The authors surveyed scientific literature focusing on how phenylalanine—an amino acid that people with PKU cannot properly metabolize—affects brain function from infancy through older adulthood. Rather than conducting new experiments, the researchers analyzed patterns in what has and hasn’t been studied, identifying which age groups have received attention and which have been neglected. The review specifically assessed studies measuring cognitive abilities such as memory, attention, processing speed, and executive function in PKU patients of various ages.
Why researchers think this happened
The authors suggest two reasons why studying very young and older PKU patients is particularly important. First, early childhood represents a critical period for brain development—neural pathways formed during infancy and toddlerhood influence cognitive and behavioral functioning throughout life. If elevated phenylalanine levels affect the developing brain in ways researchers haven’t documented, early interventions might be missed. Second, as people with PKU live longer thanks to improved management, questions arise about how the condition and its metabolic control interact with normal aging processes. The neurotoxic accumulation of phenylalanine that characterizes PKU could potentially accelerate or compound age-related cognitive decline, but without dedicated research in older adults, clinicians lack guidance on monitoring and supporting this growing population.
How to read this carefully
This is a review article identifying research gaps rather than presenting new experimental data, so it doesn’t provide definitive answers about cognitive outcomes in understudied age groups. The authors are calling attention to what we don’t know, not confirming specific cognitive patterns. Additionally, the review doesn’t quantify exactly how many studies exist for each age group or provide systematic inclusion criteria, which means readers should view this as an expert perspective rather than a comprehensive meta-analysis. The cognitive effects of PKU likely vary considerably based on individual metabolic control, genetic variations, and treatment adherence, so findings from one age group don’t necessarily predict outcomes in another.
What this means for everyday life
For families managing PKU, this review suggests that cognitive monitoring might deserve attention beyond the traditionally studied school years. Parents of infants and toddlers with PKU might ask their healthcare providers about early cognitive assessments, even if these aren’t standard practice, to establish baselines. Adults with PKU approaching middle and older age might consider this an opportunity to advocate for their own cognitive health monitoring, particularly since their doctors may have limited guidance for this life stage. For the broader PKU community, this highlights that as medical advances allow people with PKU to live full lifespans, research needs to expand accordingly—understanding how metabolic control affects the aging brain could eventually inform personalized management strategies across all life stages.